ToolGen Inaugurates Advanced Field Trial Facility in Osong, Completing 'Lab-to-Field' Commercialisation Platform for SAF Market

Cheongju, South Korea (ANTARA/PRNewswire) - ToolGen, Inc. (CEO Dr. Ryu Jong-Sang, KOSDAQ: 199800), a pioneer in CRISPR-Cas9 genome editing technology, has announced the inauguration of its advanced Genome-Edited Crop Field Trial Facility and the hosting of an Open Innovation Mini-Symposium at the Osong Innovation Circle in Cheongju, South Korea. The newly opened facility represents a significant step in translating genome editing innovations from the laboratory to commercial applications. Operating in full compliance with regulatory requirements, the facility will generate high-quality agronomic and performance data necessary to support product development, regulatory submissions, and global commercialisation. With the launch of this facility, ToolGen has established a comprehensive platform integrating genome editing, trait development, field validation, and seed product development. The facility enables the evaluation of various crop species under real cultivation conditions. Field trials will focus on drought tolerance, herbicide tolerance, and improved seed oil composition to generate robust phenotypic datasets for validating crop performance and scalability for global industrial applications. To meet growing global demand for Sustainable Aviation Fuel (SAF) feedstocks, ToolGen is leveraging its new capabilities to develop a portfolio of genome-edited industrial oil crops, including pennycress, canola, carinata, camelina, Indian mustard, and castor bean. By enhancing traits using CRISPR technology, ToolGen aims to improve yield potential and oil content, thereby providing sustainable feedstocks without competing with conventional food production systems. Moving beyond traditional licensing models, ToolGen is building a vertically integrated value chain encompassing trait development, seed production, and downstream commercial partnerships, with a focus on Australia, Southeast Asia, and Europe. ‘The Osong facility marks an important milestone in our seed business transformation from research towards product-oriented commercialisation,’ said Dan Sung, Executive Vice President of ToolGen’s Seed Business Division. CEO Dr. Ryu Jong-Sang added: ‘We are strongly positioned to contribute to the future of bioenergy in Australia, Asia, and Europe. The patent process recently underway in Europe does not affect ToolGen’s fundamental intellectual property position or strategic commercial roadmap. ToolGen remains protected by a robust, independently developed next-generation patent portfolio, which forms the basis of our long-term competitive advantage and our freedom to operate.’